Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cem...
Main Authors: | Nick Freemantle, Yingxin Xu, Florence R. Wilson, Patricia Guyot, Chieh-I Chen, Sam Keeping, Gerasimos Konidaris, Keith Chan, Andreas Kuznik, Kokuvi Atsou, Emily Glowienka, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-06-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359221105024 |
Similar Items
-
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
by: Josephine Louella Feliciano, et al.
Published: (2023-04-01) -
Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review
by: Atsou Kokuvi, et al.
Published: (2011-01-01) -
Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting
by: Shirish M. Gadgeel, et al.
Published: (2024-03-01) -
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
by: Mustafa Ozguroglu, et al.
Published: (2023-11-01) -
Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
by: Yutaka Takahara, et al.
Published: (2023-09-01)